Difference between revisions of "Aplastic anemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy")
m (Text replacement - "bloodjournal.hematologylibrary.org" to "www.bloodjournal.org")
Line 389: Line 389:
 
===References===
 
===References===
 
# Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. [https://www.nejm.org/doi/full/10.1056/NEJMoa1200931 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422737/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22762314 PubMed]
 
# Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. [https://www.nejm.org/doi/full/10.1056/NEJMoa1200931 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422737/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22762314 PubMed]
## '''Update:''' Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. [http://bloodjournal.hematologylibrary.org/content/123/12/1818.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962161/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24345753 PubMed]
+
## '''Update:''' Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. [http://www.bloodjournal.org/content/123/12/1818.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962161/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24345753 PubMed]
  
 
[[Category:Aplastic anemia regimens]]
 
[[Category:Aplastic anemia regimens]]

Revision as of 02:38, 22 June 2019

Section editors
Shruti.jpg
Shruti Chaturvedi, MBBS, MSCI
Johns Hopkins University
Baltimore, MD

LinkedIn
Tillman Benjamin-2.jpg
Benjamin Tillman, MD
Vanderbilt University
Nashville, TN
9 regimens on this page
12 variants on this page


Guidelines

BSH

Initial therapy

ATG (Horse) & Cyclosporine

back to top

Variant #1

Study Evidence Comparator Comparative Efficacy
Scheinberg et al. 2009 Phase III (C) ATG (Horse), Cyclosporine, Sirolimus Seems not superior
Tichelli et al. 2011 Phase III (C) ATG (Horse), Cyclosporine, G-CSF Seems not superior
Scheinberg et al. 2011 Phase III (C) ATG (Rabbit) & Cyclosporine Superior OS

Immunosuppressive therapy

  • Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
  • Cyclosporine A (type not specified) as follows:
    • Starting dose: 10 mg/kg in divided doses every 12 hours (15 mg/kg for children younger than 12) on day 1
    • Dose adjusted to keep trough blood level of 200 to 400 ng/ml
    • Duration: at least 6 months; among responders, CsA was tapered after 6 months with a 25% reduction in dose every 3 months for 18 more months, totaling 2 years of oral CsA (per Scheinberg et al. 2009)

Supportive medications

Variant #2

Study Evidence Comparator Comparative Efficacy
Teramura et al. 2007 Phase III (C) ATG (Horse), Cyclosporine, G-CSF Seems to have inferior hematologic response rate at 6 months

Immunosuppressive therapy

Supportive medications

  • Prednisolone (Millipred) to prevent serum sickness, as follows:
    • Days 1 to 9: 1 mg/kg/day PO
    • Days 10 to 15: 0.5 mg/kg/day PO
    • Days 16 to 21: 0.2 mg/kg/day PO

Variant #3

Study Evidence Comparator Comparative Efficacy
Marsh et al. 1999 Phase III (E) Cyclosporine Seems to have superior ORR

Immunosuppressive therapy

  • Horse ATG (Lymphoglobuline; Merieux, Lyon, France) 15 mg/kg IV once per day on days 1 to 5
  • Cyclosporine A (type not specified) as follows:
    • Starting dose: 5 mg/kg/day in two divided doses
    • Dose adjusted to keep trough blood level of 75 to 200 ng/ml
    • Duration: at least 6 months; if blood cell count continued to increase at 6 months, continued at the therapeutic dose until the blood cell count plateaued, then reduced gradually to help prevent a relapse of the aplasia, per individual clinician discretion

Supportive medications

  • Prednisolone (Millipred) to prevent serum sickness, as follows:
    • Days 5 to 13: 1 mg/kg/day PO
    • Days 14 to 20: reduced to zero over one week (tapering schedule not provided)

References

  1. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socie G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A, Bacigalupo A. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999 Apr 1;93(7):2191-5. link to original article contains verified protocol PubMed
  2. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, Omine M, Mizoguchi H. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007 Sep 15;110(6):1756-61. Epub 2007 May 25. link to original article contains verified protocol PubMed
  3. Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009 Mar;94(3):348-54. Epub 2009 Jan 30. link to original article contains verified protocol link to PMC article PubMed
  4. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011 Apr 28;117(17):4434-41. Epub 2011 Jan 13. link to original article PubMed
  5. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011 Aug 4;365(5):430-8. link to original article link to PMC article PubMed

ATG (Horse), Cyclosporine, Eltrombopag

back to top

Regimen

Study Evidence
Townsley et al. 2017 Phase I/II

This is the eltrombopag dosing used in cohort 3, which had the highest response rate. ATG and CsA dosing was not described in the manuscript but was based on Scheinberg et al. 2011.

Immunosuppressive therapy

  • Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
  • Cyclosporine A (type not specified) as follows:
    • Starting dose: 10 mg/kg in divided doses every 12 hours (15 mg/kg for children younger than 12)
    • Dose adjusted to keep trough blood level of 200 to 400 ng/ml

Supportive medications

  • Eltrombopag (Promacta) as follows:
    • Patients 2 to 5 years old: 2.5 mg/kg PO once per day
    • Patients 6 to 11 years old: 75 mg PO once per day
    • Patients 12 and older: 150 mg PO once per day
      • East or Southeast Asian participants had a 50% dose reduction
  • Pentamidine (Nebupent) (dose not specified) once per month
  • Valacyclovir (Valtrex) (dose not specified) once per day

6-month course

References

  1. Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 Apr 20;376(16):1540-1550. link to original article contains partial protocol link to PMC article PubMed

ATG (Horse), Cyclosporine, Methylprednisolone

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Frickhofen et al. 1991 Phase III (E) ATG & Methylprednisolone Seems to have superior ORR

Immunosuppressive therapy

References

  1. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H; The German Aplastic Anemia Study Group. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991 May 9;324(19):1297-304. link to original article PubMed

ATG (Horse), Cyclosporine, G-CSF

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Teramura et al. 2007 Phase III (E) ATG (Horse) & Cyclosporine Seems to have superior hematologic response rate at 6 months
Tichelli et al. 2011 Phase III (E) ATG (Horse) & Cyclosporine Seems not superior

Immunosuppressive therapy

Growth factor therapy

  • ONE of the following:
    • Filgrastim (Neupogen) as follows:
      • Days 1 to 28: 400 mcg/m2 IV once every other day
      • Days 29 to 84: 400 mcg/m2 IV once or twice per week
    • Lenograstim (Granocyte) as follows:
      • Days 1 to 28: 50 mcg/kg IV once every other day
      • Days 29 to 84: 50 mcg/kg IV once or twice per week

Supportive medications

  • Prednisolone (Millipred) to prevent serum sickness, as follows:
    • Days 1 to 9: 1 mg/kg/day PO
    • Days 10 to 15: 0.5 mg/kg/day PO
    • Days 16 to 21: 0.2 mg/kg/day PO

References

  1. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, Omine M, Mizoguchi H. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007 Sep 15;110(6):1756-61. Epub 2007 May 25. link to original article contains verified protocol PubMed
  2. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011 Apr 28;117(17):4434-41. Epub 2011 Jan 13. link to original article PubMed

ATG (Horse), Cyclosporine, Sirolimus

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Scheinberg et al. 2009 Phase III (E) ATG (Horse) & Cyclosporine Seems not superior

Immunosuppressive therapy

  • Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
  • Cyclosporine A (type not specified) as follows:
    • Starting dose: 10 mg/kg in divided doses every 12 hours (15 mg/kg for children younger than 12) on day 1
    • Dose adjusted to keep trough blood level of 200 to 400 ng/ml
    • Duration: 6 months
  • Sirolimus (Rapamune) as follows:
    • Starting dose: 2 mg/day (1 mg/m2/day in children less than 40 kg) on day 1
    • Dose adjusted to keep levels between 5 to 15 ng/ml
    • Duration: 6 months

Supportive medications

References

  1. Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009 Mar;94(3):348-54. Epub 2009 Jan 30. link to original article contains verified protocol link to PMC article PubMed

ATG (Rabbit) & Cyclosporine

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Scheinberg et al. 2011 Phase III (E) ATG (Horse) & Cyclosporine Inferior OS

Immunosuppressive therapy

Supportive medications

References

  1. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011 Aug 4;365(5):430-8. link to original article link to PMC article PubMed

Cyclosporine monotherapy

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Gluckman et al. 1992 Phase III (E) ATG (Horse) & Prednisone Seems not superior
Marsh et al. 1999 Phase III (C) ATG (Horse) & Cyclosporine Seems to have inferior ORR

Immunosuppressive therapy

  • Cyclosporine A (type not specified) as follows:
    • Starting dose: 5 mg/kg/day in two divided doses
    • Dose adjusted to keep trough blood level of 75 to 200 ng/ml
    • Duration: at least 6 months; if blood cell count continued to increase at 6 months, continued at the therapeutic dose until the blood cell count plateaued, then reduced gradually to help prevent a relapse of the aplasia, per individual clinician discretion

Supportive medications

  • Prednisolone (Millipred) to prevent serum sickness, as follows:
    • Days 5 to 13: 1 mg/kg/day PO
    • Days 14 to 20: reduced to zero over one week (tapering schedule not provided)

References

  1. Gluckman E, Esperou-Bourdeau H, Baruchel A, Boogaerts M, Briere J, Donadio D, Leverger G, Leporrier M, Reiffers J, Janvier M, Michallet M, Stryckmans P; Cooperative Group on the Treatment of Aplastic Anemia. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992 May 15;79(10):2540-6. link to original article PubMed
  2. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socie G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A, Bacigalupo A. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999 Apr 1;93(7):2191-5. link to original article contains verified protocol PubMed

Relapsed or refractory

ATG (Rabbit) & Cyclosporine

back to top

Regimen

Study Evidence
Di Bona et al. 1999 Phase II
Scheinberg et al. 2006 Phase II

To be completed

Immunosuppressive therapy

References

  1. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, Rosanelli C, Camba L, Saracco P, Lippi A, Iori AP, Porta F, De Rossi G, Comotti B, Iacopino P, Dufour C, Bacigalupo A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol. 1999 Nov;107(2):330-4. Erratum in: Br J Haematol 2000 Feb;108(2):461. De Rossi V [corrected to De Rossi G]. link to original article PubMed
  2. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006 Jun;133(6):622-7. link to original article PubMed

Eltrombopag monotherapy

back to top

Regimen

Study Evidence Efficacy
Olnes et al. 2012 Phase II RR: 44%

Growth factor therapy

  • Eltrombopag (Promacta) 50 mg PO once per day, increased by 25 mg every 2 weeks until platelet count greater than 20 x 109/L or maximum of 150 mg per day

Continued indefinitely

References

  1. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. link to original article contains verified protocol link to PMC article PubMed
    1. Update: Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. link to original article contains verified protocol link to PMC article PubMed